

EurOPDX Consortium

-

List of articles, poster presentations & talks

Articles co-published by EurOPDX Members:

M. Hidalgo, F. Amant, A. V. Biankin, E. Budinska, A. T. Byrne, C. Caldas, R. B. Clarke, S. de Jong, J. Jonkers, G. M. Maelandsmo, S. Roman-Roman, J. Seoane, L. Trusolino, A. Villanueva, **Patient-derived xenograft models: an emerging platform for translational cancer research**. *Cancer discovery* **4**, 998-1013 (2014)

E. R. Zanella, F. Galimi, F. Sassi, G. Migliardi, F. Cottino, S. M. Leto, B. Lupo, J. Erriquez, C. Isella, P. M. Comoglio, E. Medico, S. Tejpar, E. Budinska, L. Trusolino, A. Bertotti, **IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies**. *Science translational medicine* **7**, 272ra212 (2015)

Talks:

A. Bertotti, "**Current Approaches to PDX Model Generation, Maintenance and Data Tracking**". Methods Workshop "Utility of Patient-Derived Tumor Xenograft Models", American Association for Cancer Research Annual Meeting 2014, San Diego, CA, USA, chaired by Dr. Manuel Hidalgo.

S. Roman-Roman, "**The European PDX Consortium**". 6th European course of *in vivo* Preclinical Assays in Cancer Therapy, May 21-23, 2014, Institut Curie, Paris, France.

Posters:

Vinolo, E., Marangoni, E., Serra, V., Amant, F., Bertotti A., Biankin, A.V., Børresen-Dale, A.-L., Bruna, A., Budinská, E., Byrne, A.T., Caldas, C., Chang, D., Clarke, R.B., Hermans, E., Hidalgo, M., de Jong, S., Jonkers, J., López-Casas, P.P., Maelandsmo, G.M., Popovici, V., Roman-Roman, S., Seoane, J., Trusolino, L., and Villanueva, A. on behalf of the EurOPDX Consortium, **The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials**. AACR-NCI-EORTC "Molecular targets and cancer therapeutics" meeting, Boston, MA, October 2013

Additional selected bibliography from individual EurOPDX Members:

Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, UK:

P. Eirew, A. Steif, J. Khattra, G. Ha, D. Yap, H. Farahani, K. Gelmon, S. Chia, C. Mar, A. Wan, E. Laks, J. Biele, K. Shumansky, J. Rosner, A. McPherson, C. Nielsen, A. J. Roth, C. Lefebvre, A. Bashashati, C. de Souza, C. Siu, R. Aniba, J. Brimhall, A. Oloumi, T. Osako, **A. Bruna**, J. L. Sandoval, T. Algara, W. Greenwood, K. Leung, H. Cheng, H. Xue, Y. Wang, D. Lin, A. J. Mungall, R. Moore, Y. Zhao, J. Lorette, L. Nguyen, D. Huntsman, C. J. Eaves, C. Hansen, M. A. Marra, **C. Caldas**, S. P. Shah, S. Aparicio, **Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution**. *Nature* **518**, 422-426 (2015)

H. R. Ali, **O. M. Rueda**, S. F. Chin, C. Curtis, M. J. Dunning, S. A. Aparicio, **C. Caldas**, **Genome-driven integrated classification of breast cancer validated in over 7,500 samples**. *Genome biology* **15**, 431 (2014)

S. J. Dawson, D. W. Tsui, M. Murtaza, H. Biggs, **O. M. Rueda**, S. F. Chin, M. J. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo, S. Rajan, S. Humphray, J. Becq, D. Halsall, M. Wallis, D. Bentley, **C. Caldas**, N. Rosenfeld, **Analysis of circulating tumor DNA to monitor metastatic breast cancer.** *The New England journal of medicine* **368**, 1199-1209 (2013)

Centro Nacional de Investigaciones Oncológicas, Madrid, Spain:

E. Garralda, K. Paz, **P. P. Lopez-Casas**, S. Jones, A. Katz, L. M. Kann, F. Lopez-Rios, F. Sarno, **F. Al-Shahrour**, D. Vasquez, E. Bruckheimer, S. V. Angiuoli, A. Calles, L. A. Diaz, V. E. Velculescu, A. Valencia, D. Sidransky, **M. Hidalgo**, **Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **20**, 2476-2484 (2014)

R. Martinez-Garcia, D. Juan, A. Rausell, M. Munoz, N. Banos, C. Menendez, **P. P. Lopez-Casas**, D. Rico, A. Valencia, **M. Hidalgo**, **Transcriptional dissection of pancreatic tumors engrafted in mice.** *Genome medicine* **6**, 27 (2014)10.1186/gm544).

A. Calles, B. Rubio-Viqueira, **M. Hidalgo**, **Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology.** *Current protocols in pharmacology / editorial board, S.J. Enna Chapter 14*, Unit 14 26 (2013)

I. Garrido-Laguna, M. Uson, N. V. Rajeshkumar, A. C. Tan, E. de Oliveira, C. Karikari, M. C. Villaroel, A. Salomon, G. Taylor, R. Sharma, R. H. Hruban, A. Maitra, D. Laheru, B. Rubio-Viqueira, A. Jimeno, **M. Hidalgo**, **Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **17**, 5793-5800 (2011)

B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, C. Shi, K. Danenberg, P. V. Danenberg, H. Kuramochi, K. Tanaka, S. Singh, H. Salimi-Moosavi, N. Bouraoud, M. L. Amador, S. Altiock, P. Kulesza, C. Yeo, W. Messersmith, J. Eshleman, R. H. Hruban, A. Maitra, **M. Hidalgo**, **An in vivo platform for translational drug development in pancreatic cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **12**, 4652-4661 (2006)

Institut Català d'Oncologia - Bellvitge Biomedical Research Institute, Barcelona, Spain:

C. Ambrogio, F. J. Carmona, A. Vidal, M. Falcone, P. Nieto, O. A. Romero, S. Puertas, M. Vizoso, E. Nadal, T. Poggio, M. Sanchez-Cespedes, M. Esteller, F. Mulero, C. Voena, R. Chiarle, M. Barbacid, D. Santamaria, **A. Villanueva**, **Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.** *Cancer research* **74**, 5978-5988 (2014)

M. Juliachs, C. Munoz, C. A. Moutinho, A. Vidal, E. Condom, M. Esteller, M. Graupera, **O. Casanovas**, J. R. Germa, **A. Villanueva**, **F. Vinals**, **The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **20**, 658-667 (2014)

M. Juliachs, A. Vidal, X. G. Del Muro, J. M. Piulats, E. Condom, **O. Casanovas**, M. Graupera, J. R. Germa, **A. Villanueva**, **F. Vinals**, **Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.** *BMC cancer* **13**, 382 (2013)

A. Vidal, C. Munoz, M. J. Guillen, J. Moreto, S. Puertas, M. Martinez-Iniesta, A. Figueras, L. Padulles, F. J. Garcia-Rodriguez, M. Berdiel-Acer, **M. A. Pujana**, R. Salazar, M. Gil-Martin, L. Marti, J. Ponce, D. G. Mollevi, G. Capella, E. Condom, **F. Vinals**, D. Huertas, C. Cuevas, M. Esteller, P. Aviles, **A. Villanueva**, **Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 5399-5411 (2012)

Institut Curie, Paris, France:

M. Nunes, P. Vrignaud, S. Vacher, S. Richon, A. Lievre, W. Cacheux, L. B. Weiswald, G. Massonnet, S. Chatean-Joubert, A. Nicolas, C. Dib, W. Zhang, J. Watters, D. Bergstrom, **S. Roman-Roman**, I. Bieche, **V. Dangles-Marie**, **Evaluating patient-derived colorectal cancer-xenografts as preclinical models by comparison with patient clinical data.** *Cancer research* (2015); published online EpubFeb 24

P. de Cremoux, M. Dalvai, O. N'Doye, F. Moutahir, G. Rolland, O. Chouchane-Mlik, F. Assayag, J. Lehmann-Che, L. Kraus-Berthie, A. Nicolas, B. P. Lockhart, **E. Marangoni**, H. de The, S. Depil, K. Bystricky, **D. Decaudin**, **HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.** *Breast cancer research and treatment* **149**, 81-89 (2015)

N. Amirouchene-Angelozzi, **F. Nemati**, D. Gentien, A. Nicolas, A. Dumont, G. Carita, J. Camonis, L. Desjardins, N. Cassoux, S. Piperno-Neumann, P. Mariani, X. Sastre, **D. Decaudin**, **S. Roman-Roman**, **Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.** *Molecular oncology* **8**, 1508-1520 (2014)

L. de Plater, A. Vincent-Salomon, F. Berger, A. Nicolas, S. Vacher, E. Gravier, A. Thuleau, N. Karboul, M. Richardson, C. Elbaz, **E. Marangoni**, I. Bieche, X. Paoletti, **S. Roman-Roman**, P. A. Culp, B. Asselain, V. Dieras, **D. Decaudin**, **Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.** *PLoS one* **9**, e104227 (2014)

P. Cottu, I. Bieche, F. Assayag, R. El Botty, S. Chateau-Joubert, A. Thuleau, T. Bagarre, B. Albaud, A. Rapinat, D. Gentien, P. de la Grange, V. Sibut, S. Vacher, R. Hatem, J. L. Servely, J. J. Fontaine, **D. Decaudin**, J. Y. Pierga, **S. Roman-Roman**, **E. Marangoni**, **Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **20**, 4314-4325 (2014)

C. Laurent, D. Gentien, S. Piperno-Neumann, **F. Nemati**, A. Nicolas, B. Tesson, L. Desjardins, P. Mariani, A. Rapinat, X. Sastre-Garau, J. Couturier, P. Hupe, L. de Koning, T. Dubois, **S. Roman-Roman**, M. H. Stern, E. Barillot, J. W. Harbour, S. Saule, **D. Decaudin**, **Patient-derived xenografts recapitulate molecular features of human uveal melanomas.** *Molecular oncology* **7**, 625-636 (2013)

A. Romanelli, A. Clark, F. Assayag, S. Chateau-Joubert, M. F. Poupon, J. L. Servely, J. J. Fontaine, X. Liu, E. Spooner, S. Goodstal, P. de Cremoux, I. Bieche, **D. Decaudin**, **E. Marangoni**, **Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.** *Molecular cancer therapeutics* **11**, 2693-2703 (2012)

F. Reyat, C. Guyader, C. Decraene, C. Lucchesi, N. Auger, F. Assayag, L. De Plater, D. Gentien, M. F. Poupon, P. Cottu, P. De Cremoux, P. Gestraud, A. Vincent-Salomon, J. J. Fontaine, **S. Roman-Roman**, O. Delattre, **D. Decaudin**, **E. Marangoni**, **Molecular profiling of patient-derived breast cancer xenografts.** *Breast cancer research : BCR* **14**, R11 (2012)

Istituto Europeo di Oncologia, Milan, Italy:

M. V. Verga Falzacappa, C. Ronchini, M. Faretta, I. Iacobucci, A. Ghelli Luserna Di Rora, G. Martinelli, L. H. Meyer, K. M. Debatin, S. Orecchioni, F. Bertolini, **P. G. Pelicci**, **The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias.** *Molecular cancer therapeutics*, (2015)

M. Mallardo, A. Caronno, G. Pruneri, P. R. Raviele, A. Viale, **P. G. Pelicci**, E. Colombo, **NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model.** *Leukemia* **27**, 2248-2251 (2013)

A. Insinga, A. Cicalese, M. Faretta, B. Gallo, L. Albano, S. Ronzoni, L. Furia, A. Viale, **P. G. Pelicci**, **DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing**

divisions. Proceedings of the National Academy of Sciences of the United States of America **110**, 3931-3936 (2013)

E. Aladowicz, L. Ferro, G. C. Vitali, E. Venditti, L. Fornasari, **L. Lanfrancone**, **Molecular networks in melanoma invasion and metastasis. Future oncology** **9**, 713-726 (2013)

M. Y. Turco, L. Furia, A. Dietze, L. Fernandez Diaz, S. Ronzoni, A. Sciuillo, A. Simeone, D. Constam, M. Faretta, **L. Lanfrancone**, **Cellular heterogeneity during embryonic stem cell differentiation to epiblast stem cells is revealed by the ShcD/RaLP adaptor protein. Stem cells** **30**, 2423-2436 (2012)

L. Pasini, M. Y. Turco, L. Luzi, E. Aladowicz, E. Fagiani, **L. Lanfrancone**, **Melanoma: targeting signaling pathways and RaLP. Expert opinion on therapeutic targets** **13**, 93-104 (2009)

Ludwig Cancer Institute, University of Lausanne, Switzerland:

S. Bron, L. Henry, E. Faes-van't Hull, R. Turrini, **D. Vanhecke**, N. Guex, A. Ifticene-Treboux, E. M. Iancu, A. Semilietof, N. Rufer, H. Lehr, I. Xenarios, **G. Coukos**, J-F. Delaloye, M. Doucey, **TIE-2-expressing monocytes are lymphangiogenic and incorporate specifically into lymphatics of human breast cancer. Submitted to Oncol. Immunol.** (2015)

E. Lanitis, M. Irving, **G. Coukos**, **Targeting the tumor vasculature to enhance T cell activity. Current opinion in immunology** **33C**, 55-63 (2015)

S. P. Santoro, S. Kim, G. T. Motz, D. Alatzoglou, C. Li, M. Irving, D. J. Powell, Jr., **G. Coukos**, **T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer immunology research** **3**, 68-84 (2015)

C. Li, A. M. Chacko, J. Hu, K. Hasegawa, J. Swails, L. Grasso, W. S. El-Deiry, N. Nicolaides, V. R. Muzykantov, C. R. Divgi, **G. Coukos**, **Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer biology & therapy** **15**, 443-451 (2014)

G. T. Motz, **G. Coukos**, **Deciphering and reversing tumor immune suppression. Immunity** **39**, 61-73 (2013)

Masaryk University, Brno, Czech Republic:

N. F. Jensen, J. Stenvang, M. K. Beck, B. Hanakova, K. C. Belling, K. N. Do, B. Viuff, S. B. Nygard, R. Gupta, M. H. Rasmussen, L. S. Tarpgaard, T. P. Hansen, **E. Budinska**, P. Pfeiffer, F. Bosman, S. Tejpar, A. Roth, M. Delorenzi, C. L. Andersen, M. U. Romer, N. Brunner, J. M. Moreira, **Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Molecular oncology**, (2015)

P. J. Belmont, **E. Budinska**, P. Jiang, M. J. Sinnamon, E. Coffee, J. Roper, T. Xie, P. A. Rejto, S. Derkits, O. J. Sansom, M. Delorenzi, S. Tejpar, K. E. Hung, E. S. Martin, **Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease. Disease models & mechanisms** **7**, 613-623 (2014)

E. Budinska, **V. Popovici**, S. Tejpar, G. D'Ario, N. Lapique, K. O. Sikora, A. F. Di Narzo, P. Yan, J. G. Hodgson, S. Weinrich, F. Bosman, A. Roth, M. Delorenzi, **Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. The Journal of pathology** **231**, 63-76 (2013)

V. Popovici, **E. Budinska**, F. T. Bosman, S. Tejpar, A. D. Roth, M. Delorenzi, **Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC cancer** **13**, 439 (2013)

Netherlands Cancer Institute, Amsterdam, The Netherlands:

P. Bouwman, H. van der Gulden, I. van der Heijden, R. Drost, C. N. Klijn, P. Prasetyanti, M. Pieterse, E. Wientjens, J. Seibler, F. B. Hogervorst, **J. Jonkers**, **A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer discovery** **3**, 1142-1155 (2013)

E. M. Michalak, K. Nacerddine, A. Pietersen, V. Beuger, I. Pawlitzky, P. Cornelissen-Steijger, E. Wientjens, E. Tanger, J. Seibler, M. van Lohuizen, **J. Jonkers**, **Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool**. *Stem cells* **31**, 1910-1920 (2013); published online EpubSep (10.1002/stem.1437).

C. Klijn, M. J. Koudijs, J. Kool, J. ten Hoeve, M. Boer, J. de Moes, W. Akhtar, M. van Miltenburg, A. Vendel-Zwaagstra, M. J. Reinders, D. J. Adams, M. van Lohuizen, J. Hilkens, **L. F. Wessels**, **J. Jonkers**, **Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors**. *PloS one* **8**, e62113 (2013)

J. Muller, O. Krijgsman, J. Tsoi, L. Robert, W. Hugo, C. Song, X. Kong, P. A. Possik, P. D. Cornelissen-Steijger, M. H. Foppen, **K. Kemper**, C. R. Goding, U. McDermott, C. Blank, J. Haanen, T. G. Graeber, A. Ribas, R. S. Lo, **D. S. Peeper**, **Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma**. *Nature communications* **5**, 5712 (2014)

K. Kemper, P. L. de Goeje, **D. S. Peeper**, R. van Amerongen, **Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy**. *Cancer research* **74**, 5937-5941 (2014)

Oslo University Hospital, Oslo, Norway:

N. Skrbo, G. O. Hjortland, A. Kristian, R. Holm, S. Nord, L. Prasmickaite, O. Engebraaten, **G. M. Maelandsmo**, T. Sorlie, **K. Andersen**, **Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft**. *PloS one* **9**, e113278 (2014)

M. T. Grinde, N. Skrbo, S. A. Moestue, E. A. Rodland, E. Borgan, A. Kristian, B. Sitter, T. F. Bathen, **A. L. Borresen-Dale**, **G. M. Maelandsmo**, O. Engebraaten, T. Sorlie, E. Marangoni, I. S. Gribbestad, **Interplay of choline metabolites and genes in patient-derived breast cancer xenografts**. *Breast cancer research : BCR* **16**, R5 (2014)

E. M. Lindholm, M. Krohn, S. Iadevaia, A. Kristian, G. B. Mills, **G. M. Maelandsmo**, O. Engebraaten, **Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations**. *Clinical cancer research : an official journal of the American Association for Cancer Research* **20**, 404-412 (2014)

B. Engesaeter, O. Engebraaten, V. A. Florenes, **G. M. Maelandsmo**, **Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma**. *PloS one* **7**, e45492 (2012)

E. M. Lindholm, A. Kristian, H. Nalwoga, K. Kruger, S. Nygard, L. A. Akslen, **G. M. Maelandsmo**, O. Engebraaten, **Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts**. *Molecular oncology* **6**, 418-427 (2012)

L. Prasmickaite, N. Skrbo, H. K. Hoifodt, Z. Suo, O. Engebraaten, H. P. Gullestad, S. Aamdal, O. Fodstad, **G. M. Maelandsmo**, **Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells**. *Pigment cell & melanoma research* **23**, 449-451 (2010)

Royal College of Surgeons in Ireland, Dublin, Ireland:

M. A. Jarzabek, V. Amberger-Murphy, J. J. Callanan, C. Gao, A. M. Zagozdzon, L. Shiels, J. Wang, K. L. Ligon, B. E. Rich, P. Dicker, W. M. Gallagher, J. H. Prehn, **A. T. Byrne**, **Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models**. *British journal of cancer* **111**, 2275-2286 (2014)

K. J. Sweeney, M. A. Jarzabek, P. Dicker, D. F. O'Brien, J. J. Callanan, **A. T. Byrne**, J. H. Prehn, **Validation of an imageable surgical resection animal model of Glioblastoma (GBM)**. *Journal of neuroscience methods* **233**, 99-104 (2014)

M. A. Jarzabek, P. C. Huszthy, K. O. Skaftnesmo, E. McCormack, P. Dicker, J. H. Prehn, R. Bjerkvig, **A. T. Byrne**, **In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme**. *Molecular imaging* **12**, 161-172 (2013)

A. T. Byrne, L. Ross, J. Holash, M. Nakanishi, L. Hu, J. I. Hofmann, G. D. Yancopoulos, R. B. Jaffe, **Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **9**, 5721-5728 (2003)

M. A. Jarzabek, K. J. Sweeney, R. L. Evans, A. H. Jacobs, R. Stupp, D. O'Brien, M. S. Berger, J. H. Prehn, **A. T. Byrne**, **Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary.** *Drug discovery today* **18**, 1052-1066 (2013)

University of Glasgow, Institute of Cancer Sciences, Glasgow, UK:

N. Waddell, M. Pajic, A. M. Patch, **D. K. Chang**, K. S. Kassahn, P. Bailey, A. L. Johns, D. Miller, K. Nones, K. Quek, M. C. Quinn, A. J. Robertson, M. Z. Fadlullah, T. J. Bruxner, A. N. Christ, I. Harliwong, S. Idrisoglu, S. Manning, C. Nourse, E. Nourbakhsh, S. Wani, P. J. Wilson, E. Markham, N. Cloonan, M. J. Anderson, J. L. Fink, O. Holmes, S. H. Kazakoff, C. Leonard, F. Newell, B. Poudel, S. Song, D. Taylor, N. Waddell, S. Wood, Q. Xu, J. Wu, M. Pinese, M. J. Cowley, H. C. Lee, M. D. Jones, A. M. Nagrial, J. Humphris, L. A. Chantrill, V. Chin, A. M. Steinmann, A. Mawson, E. S. Humphrey, E. K. Colvin, A. Chou, C. J. Scarlett, A. V. Pinho, M. Giry-Laterriere, I. Rooman, J. S. Samra, J. G. Kench, J. A. Pettitt, N. D. Merrett, C. Toon, K. Epari, N. Q. Nguyen, A. Barbour, N. Zeps, N. B. Jamieson, J. S. Graham, S. P. Niclou, R. Bjerkvig, R. Grutzmann, D. Aust, R. H. Hruban, A. Maitra, C. A. Iacobuzio-Donahue, C. L. Wolfgang, R. A. Morgan, R. T. Lawlor, V. Corbo, C. Bassi, M. Falconi, G. Zamboni, G. Tortora, M. A. Tempero, I. Australian Pancreatic Cancer Genome, A. J. Gill, J. R. Eshleman, C. Pilarsky, A. Scarpa, E. A. Musgrove, J. V. Pearson, **A. V. Biankin**, S. M. Grimmond, **Whole genomes redefine the mutational landscape of pancreatic cancer.** *Nature* **518**, 495-501 (2015)

M. Pajic, C. J. Scarlett, **D. K. Chang**, R. L. Sutherland, **A. V. Biankin**, **Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.** *Human genetics* **130**, 93-101 (2011)

University of Manchester, Institute of Cancer Sciences, Manchester, UK (Breakthrough Breast Cancer Unit):

K. E. Williams, N. J. Bundred, G. Landberg, **R. B. Clarke**, G. Farnie, **Focal adhesion kinase and wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.** *Stem cells* **33**, 327-341 (2015)

M. P. Ablett, C. S. O'Brien, A. H. Sims, G. Farnie, **R. B. Clarke**, **A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.** *Oncotarget* **5**, 599-612 (2014)

J. K. Singh, G. Farnie, N. J. Bundred, B. M. Simoes, A. Shergill, G. Landberg, S. J. Howell, **R. B. Clarke**, **Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 643-656 (2013)

H. Harrison, G. Farnie, S. J. Howell, R. E. Rock, S. Stylianou, K. R. Brennan, N. J. Bundred, **R. B. Clarke**, **Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.** *Cancer research* **70**, 709-718 (2010)

University Medical Centre Groningen, The Netherlands:

A. Meijer, F. A. Kruyt, A. G. van der Zee, H. Hollema, P. Le, K. A. ten Hoor, G. M. Groothuis, W. J. Quax, E. G. de Vries, **S. de Jong**, **Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.** *British journal of cancer* **109**, 2685-2695 (2013)

A. R. van der Bilt, A. G. Terwisscha van Scheltinga, H. Timmer-Bosscha, C. P. Schroder, L. Pot, J. G. Kosterink, A. G. van der Zee, M. N. Lub-de Hooge, **S. de Jong**, E. G. de Vries, A. K. Reyners, **Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for**

the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 6306-6314 (2012)

E. W. Duiker, A. Meijer, A. R. van der Bilt, G. J. Meersma, N. Kooi, A. G. van der Zee, E. G. de Vries, **S. de Jong**, **Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.** *British journal of cancer* **104**, 1278-1287 (2011)

E. W. Duiker, E. G. de Vries, D. Mahalingam, G. J. Meersma, W. Boersma-van Ek, H. Hollema, M. N. Lub-de Hooge, G. M. van Dam, R. H. Cool, W. J. Quax, A. Samali, A. G. van der Zee, **S. de Jong**, **Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **15**, 2048-2057 (2009)

A. P. Crijns, R. S. Fehrmann, **S. de Jong**, F. Gerbens, G. J. Meersma, H. G. Klip, H. Hollema, R. M. Hofstra, G. J. te Meerman, E. G. de Vries, A. G. van der Zee, **Survival-related profile, pathways, and transcription factors in ovarian cancer.** *PLoS medicine* **6**, e24 (2009)

University of Torino, Candiolo Cancer Institute, Turin, Italy:

C. Isella, A. Terrasi, S. E. Bellomo, C. Petti, G. Galatola, A. Muratore, A. Mellano, R. Senetta, A. Cassenti, C. Sonetto, G. Inghirami, **L. Trusolino**, Z. Fekete, M. De Ridder, P. Cassoni, G. Storme, **A. Bertotti**, **E. Medico**, **Stromal contribution to the colorectal cancer transcriptome.** *Nature genetics*, (2015)

A. Bardelli, **S. Corso**, **A. Bertotti**, S. Hobor, E. Valtorta, G. Siravegna, A. Sartore-Bianchi, E. Scala, A. Cassingena, D. Zecchin, M. Apicella, G. Migliardi, F. Galimi, C. Lauricella, C. Zanon, T. Perera, S. Veronese, G. Corti, A. Amatu, M. Gambacorta, L. A. Diaz, Jr., M. Sausen, V. E. Velculescu, P. Comoglio, **L. Trusolino**, F. Di Nicolantonio, **S. Giordano**, S. Siena, **Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.** *Cancer discovery* **3**, 658-673 (2013)

A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti, C. Isella, D. Cora, F. Di Nicolantonio, M. Buscarino, C. Petti, D. Ribero, N. Russolillo, A. Muratore, P. Massucco, A. Pisacane, L. Molinaro, E. Valtorta, A. Sartore-Bianchi, M. Risio, L. Capussotti, M. Gambacorta, S. Siena, **E. Medico**, A. Sapino, S. Marsoni, P. M. Comoglio, A. Bardelli, **L. Trusolino**, **A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.** *Cancer discovery* **1**, 508-523 (2011)

F. Galimi, D. Torti, F. Sassi, C. Isella, D. Cora, S. Gastaldi, D. Ribero, A. Muratore, P. Massucco, D. Siatis, G. Paraluppi, F. Gonella, F. Maione, A. Pisacane, E. David, B. Torchio, M. Risio, M. Salizzoni, L. Capussotti, T. Perera, **E. Medico**, M. F. Di Renzo, P. M. Comoglio, **L. Trusolino**, **A. Bertotti**, **Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **17**, 3146-3156 (2011)

Vall d'Hebron Institute of Oncology, Barcelona, Spain:

M. Zacarias-Fluck, B. Morancho, R. Vicario, A. Luque-García, C. Ferrer-Ramón, M. Escorihuela, J. Villanueva, I. Rubio, **J. Arribas**, **Cellular senescence promotes the growth of HER2-positive breast cancers through IL-6 signaling.** *J Natl Cancer Inst.* In press. (2015)

J. L. Parra-Palau, B. Morancho, V. Peg, M. Escorihuela, M. Scaltriti, R. Vicario, M. Zacarias-Fluck, K. Pedersen, A. Pandiella, P. Nuciforo, V. Serra, J. Cortes, J. Baselga, C. M. Perou, A. Prat, I. T. Rubio, **J. Arribas**, **Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.** *Journal of the National Cancer Institute* **106**, (2014)

I. Puig, I. Chicote, S. P. Tenbaum, O. Arques, J. R. Herance, J. D. Gispert, J. Jimenez, S. Landolfi, K. Caci, H. Allende, L. Mendizabal, D. Moreno, R. Charco, E. Espin, A. Prat, M. E. Elez, G. Argiles, A. Vivancos, J. Tabernero, S. Rojas, **H. G. Palmer**, **A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.** *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 6787-6801 (2013)

S. P. Tenbaum, P. Ordonez-Moran, I. Puig, I. Chicote, O. Arques, S. Landolfi, Y. Fernandez, J. R. Herance, J. D. Gispert, L. Mendizabal, S. Aguilar, S. Ramon y Cajal, S. Schwartz, Jr., A. Vivancos, E. Espin, S. Rojas, J. Baselga, J. Tabernero, A. Munoz, **H. G. Palmer, beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.** *Nature medicine* **18**, 892-901 (2012)

P. J. Eichhorn, L. Rodon, A. Gonzalez-Junca, A. Dirac, M. Gili, E. Martinez-Saez, C. Aura, I. Barba, V. Peg, A. Prat, I. Cuartas, J. Jimenez, D. Garcia-Dorado, J. Sahuquillo, R. Bernards, J. Baselga, **J. Seoane, USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma.** *Nature medicine* **18**, 429-435 (2012)

J. Anido, A. Saez-Borderias, A. Gonzalez-Junca, L. Rodon, G. Folch, M. A. Carmona, R. M. Prieto-Sanchez, I. Barba, E. Martinez-Saez, L. Prudkin, I. Cuartas, C. Raventos, F. Martinez-Ricarte, M. A. Poca, D. Garcia-Dorado, M. M. Lahn, J. M. Yingling, J. Rodon, J. Sahuquillo, J. Baselga, **J. Seoane, TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.** *Cancer cell* **18**, 655-668 (2010)

V. Serra, P. J. Eichhorn, C. Garcia-Garcia, Y. H. Ibrahim, L. Prudkin, G. Sanchez, O. Rodriguez, P. Anton, J. L. Parra, S. Marlow, M. Scaltriti, J. Perez-Garcia, A. Prat, J. Arribas, W. C. Hahn, S. Y. Kim, J. Baselga, **RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.** *The Journal of clinical investigation* **123**, 2551-2563 (2013)

Y. H. Ibrahim, C. Garcia-Garcia, **V. Serra**, L. He, K. Torres-Lockhart, A. Prat, P. Anton, P. Cozar, M. Guzman, J. Grueso, O. Rodriguez, M. T. Calvo, C. Aura, O. Diez, I. T. Rubio, J. Perez, J. Rodon, J. Cortes, L. W. Ellisen, M. Scaltriti, J. Baselga, **PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.** *Cancer discovery* **2**, 1036-1047 (2012)

D. Annibali, J. R. Whitfield, E. Favuzzi, T. Jauset, E. Serrano, I. Cuartas, S. Redondo-Campos, G. Folch, A. Gonzalez-Junca, N. M. Sodir, D. Masso-Valles, M. E. Beaulieu, L. B. Swigart, M. M. Mc Gee, M. P. Somma, S. Nasi, J. Seoane, G. I. Evan, **L. Soucek, Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.** *Nature communications* **5**, 4632 (2014)

D. Massó-Vallés, T. Jauset, E. Serrano, N. M. Sodir, K. Pedersen, N. I. Affara, J. R. Whitfield, M.-E. Beaulieu, G. I. Evan, L. Elias, J. Arribas, **L. Soucek, Ibrutinib exerts potent anti-fibrotic and anti-tumor activities in mouse models of pancreatic adenocarcinoma.** *Cancer Research*. In press. (2015)